A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ibrutinib (Primary) ; Safimaltib (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Focus Adverse reactions
Sponsors Janssen Research & Development

05 Dec 2024 Planned End Date changed from 31 Dec 2026 to 30 Apr 2025.
05 Dec 2024 Planned primary completion date changed from 25 Nov 2024 to 30 Apr 2025.
16 Aug 2024 Planned End Date changed from 25 Nov 2024 to 31 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com